ECSP088477A - DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES - Google Patents
DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLESInfo
- Publication number
- ECSP088477A ECSP088477A EC2008008477A ECSP088477A ECSP088477A EC SP088477 A ECSP088477 A EC SP088477A EC 2008008477 A EC2008008477 A EC 2008008477A EC SP088477 A ECSP088477 A EC SP088477A EC SP088477 A ECSP088477 A EC SP088477A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- disorders
- useful
- compounds
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 206010014612 Encephalitis viral Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 201000002498 viral encephalitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos novedosos de la fórmula estructural (I) son antagonistas y/o agonistas inversos del receptor canabinoide-1 (CB1) y son útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor CB1. Los compuestos de la presente invención son útiles como fármacos que actúan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migraña, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis múltiple y síndrome de Guillain-Barré y las secuelas inflamatorias de la encefalitis vírica, accidentes vasculares cerebrales, y traumatismo craneal, trastornos de ansiedad, estrés, epilepsia, enfermedad de Parkinson, trastornos del movimiento, y esquizofrenia. Los compuestos también son útiles para el tratamiento de trastornos de abuso de sustancias, para el tratamiento de obesidad o trastornos de la alimentación, así como para el tratamiento de asma, estreñimiento, pseudo-obstrucción intestinal crónica, y cirrosis hepática.Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the cannabinoid-1 receptor (CB1) and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as drugs that act centrally in the treatment of psychosis, memory impairments, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuroinflammatory disorders including multiple sclerosis and Guillain-Barré syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, for the treatment of obesity or eating disorders, as well as for the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and liver cirrhosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088477A true ECSP088477A (en) | 2008-06-30 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008477A ECSP088477A (en) | 2005-11-28 | 2008-05-27 | DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (en) |
| KR (1) | KR20080073721A (en) |
| AR (1) | AR058199A1 (en) |
| BR (1) | BRPI0619018A2 (en) |
| CR (1) | CR10014A (en) |
| DO (1) | DOP2006000261A (en) |
| EC (1) | ECSP088477A (en) |
| IL (1) | IL191586A0 (en) |
| MA (1) | MA30086B1 (en) |
| NO (1) | NO20082919L (en) |
| PE (1) | PE20070647A1 (en) |
| RU (1) | RU2008126248A (en) |
| SV (1) | SV2009002917A (en) |
| TW (1) | TW200804317A (en) |
| WO (1) | WO2007062193A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| CA2703465A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| US9440948B2 (en) | 2010-09-03 | 2016-09-13 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| EP2766349B1 (en) | 2011-03-08 | 2016-06-01 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805817B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION |
| FR2805818B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2805810B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION |
| AU2004252109B2 (en) * | 2003-06-11 | 2010-04-08 | Merck Sharp & Dohme Corp. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| AU2006242219A1 (en) * | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/en unknown
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/en not_active Withdrawn
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/en not_active IP Right Cessation
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/en not_active Application Discontinuation
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en not_active Ceased
- 2006-11-22 TW TW095143274A patent/TW200804317A/en unknown
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/en unknown
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/en not_active Application Discontinuation
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/en not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/en unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/en not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/en unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20070647A1 (en) | 2007-08-11 |
| CR10014A (en) | 2008-07-29 |
| NO20082919L (en) | 2008-08-27 |
| AR058199A1 (en) | 2008-01-23 |
| EP1954692A1 (en) | 2008-08-13 |
| IL191586A0 (en) | 2008-12-29 |
| BRPI0619018A2 (en) | 2016-11-29 |
| DOP2006000261A (en) | 2007-07-15 |
| KR20080073721A (en) | 2008-08-11 |
| WO2007062193A1 (en) | 2007-05-31 |
| RU2008126248A (en) | 2010-01-10 |
| TW200804317A (en) | 2008-01-16 |
| MA30086B1 (en) | 2008-12-01 |
| SV2009002917A (en) | 2009-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP056207A (en) | DERIVATIVES OF 3-RENT AND 3-ALQUENILAZETIDINA REPLACED | |
| ECSP045289A (en) | SUBSTITUTED AMIDAS | |
| ECSP088477A (en) | DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES | |
| DE60316829D1 (en) | SUBSTITUTED FUROÄ2,3-BÜPYRIDINE DERIVATIVES | |
| DE60334787D1 (en) | SUBSTITUTED AMIDE | |
| EP1492784A4 (en) | 2,3-DIPHENYL-PYRIDINES SUBSTITUTED | |
| ATE501151T1 (en) | SUBSTITUTED PYRANO Ä2, 3 - BUPYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | |
| WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
| WO2008024284A3 (en) | Sulfonylated piperazines as cannabinoid-1 receptor modulators | |
| WO2003063781A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| WO2005027837A3 (en) | Substituted sulfonamides | |
| WO2004029204A3 (en) | Substituted pyrimidines | |
| WO2004058145A3 (en) | Substituted amides | |
| WO2003086288A3 (en) | Bicyclic amides | |
| ATE452890T1 (en) | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | |
| WO2007136607A3 (en) | Substituted esters as cannabinoid-1 receptor modulators | |
| ECSP19043120A (en) | PYRROLOPYRIMIDINES AS POTENTIALS OF CFTR | |
| WO2007064566A3 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| WO2006041797A3 (en) | Acyclic hydrazides as cannabinoid receptor modulators | |
| CL2008000394A1 (en) | COMPOUNDS DERIVED FROM AZABICICLOALCANO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT DISORDERS ASSOCIATED WITH THE DISEASE OF ALZHEIMER, PARKINSON, PSYCHIATRIC PATHOLOGIES, CEREBRAL VASCULAR ACCIDENTS, SINDR | |
| WO2014014698A3 (en) | Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof | |
| DE602006013040D1 (en) | SUBSTITUTED PYRADINONE DERIVATIVES AS ALPHA2 ADRENORE RECEPTOR ANTAGONISTS | |
| DOP2004001060A (en) | CB1 MODULATING COMPOUNDS |